Dynavax Technologies Corporation (DVAX) Stock: A Biotechnology Stock That’s Seeing Strong Declines


Dynavax Technologies Corporation (DVAX) is working its way for to the bottom in the market today. The company, focused on the biotechnology space, is presently priced at $3.72 after a move down of 0.00% so far today. As it relates to biotech companies, there are several factors that have the ability to cause movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories relating to DVAX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-03-19 04:05PM Dynavax to Present at the William Blair & Co. Annual Growth Stock Conference
02:15PM Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavaxs SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting
Jun-01-19 02:15PM Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting
May-27-19 05:00AM Dynavax (DVAX) to Cut Jobs and Focus on Vaccine Business
May-26-19 05:03PM The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Nonetheless, any time investors are making a decision with regard to investing, prospective investors should take a look at far more than news, this is especially the case in the generally speculative biotech industry. Here’s what’s happening with Dynavax Technologies Corporation.

How DVAX Has Been Trending

Although a move down on a single session, like the move that we’re seeing from Dynavax Technologies Corporation may cause fear in some investors, that by itself shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It’s generally smart to take a look at trends further out than a single trading day. When it comes to DVAX, here are the trends that investors have experienced:

  • Past 5 Sessions – Over the last five trading sessions, DVAX has generated a change in price amounting to -21.52%.
  • Past 30 Days – The return from Dynavax Technologies Corporation over the past 30 days comes to -52.85%.
  • Quarterly – Throughout the last 3 months, the company has generated a return on investment that comes to -56.74%
  • Past 6 Months – Over the previous 6 months, we have seen a change that amounts to -64.71% from the stock.
  • This Year So Far – Since the open of this year DVAX has generated a return on investment of -59.34%.
  • Annually – Lastly, throughout the last full year, we’ve seen a change that comes to -76.31% from DVAX. Over this period, the stock has sold at a high price of -77.66% and a low of 0.54%.

Important Ratios

Looking at a few ratios having to do with a stock can provide prospective investors an understanding of how risky and/or potentially profitable a pick might be. Here are a few of the most important ratios to consider when digging into DVAX.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors are expecting that the price of the stock is headed for declines. Across the sector, biotech stocks tend to come with a higher short ratio. However, we also see a lot of short squeezes in the space. Nonetheless, when it comes to Dynavax Technologies Corporation, it’s short ratio clocks in at 13.69.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure If a company is able to cover its debts as they mature based on current assets or quick assets. Because many biotech companies are reliant on continued support from investors, the current and quick ratios can seem bad. However, several good picks in the biotechnology sector come with strong quick and current ratios. When it comes to DVAX, the quick and current ratios add up to 4.60 and 5.30 respectively.  

Book To Share Value – The book to share value compares the the share price to the book value of assets owned by the company. when it comes to Dynavax Technologies Corporation, the book to share value ratio comes in at 0.68.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the value of the company’s stock. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re interested in a stock in the biotechnology sector, this is a very important ratio to look into. In this case, the cash to share value ratio is 2.78.

How Analysts Feel About Dynavax Technologies Corporation

Although it’s not a smart idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a smart idea to consider their opinions in order to validate your own when it comes to making an investment decision in the biotech sector. Below you’ll find the most recent moves that we have seen from analysts when it comes to DVAX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-27-19 Reiterated Cantor Fitzgerald Overweight $32 → $28
May-10-18 Upgrade JP Morgan Neutral → Overweight
Mar-08-18 Reiterated Cantor Fitzgerald Overweight $25 → $27
Feb-14-18 Downgrade JP Morgan Overweight → Neutral
Sep-25-17 Reiterated RBC Capital Mkts Outperform $26 → $28

What Are Big Money Players Doing With Dynavax Technologies Corporation

An interesting fact that I’ve come to understand in my brief time as an intelligence is that good investors tend to follow the moves made by big money players. In other words, investors that are looking to keep their investments relatively safe will follow investments made by institutional investors as well as insiders. With that said, is big money interested in regard to DVAX? Here’s the information:

  • Institutional Investors – Currently, institutional investors own 82.50% of DVAX. However, it’s worth mentioning that institutional ownership has seen a move in the amount of -0.26% over the last 3 months.
  • Investors On The Inside – When it comes to insiders, those close to the company currently own 1.40% of Dynavax Technologies Corporation. Insider ownership of the company has moved -14.12% over the last quarter.

How Many Shares Of DVAX Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 65.86M shares of Dynavax Technologies Corporation outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, DVAX has a float of 64.08M.

I also like to pay attention to the short percent. After all, if a high percentage of the float available for trading is sold short, the overall opinion among traders is that the company is headed for a steep decline. As far as it relates to DVAX, the percentage of the float that is shorted is 25.65%. Most traders believe that a concerning short percent of the float is anything over 40%. Through my work, I have seen that any short percent of the float over 26% is generally a a play that could prove to be very risky.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.14. In the current quarter, analysts see the company producing earnings in the amount of $-0.59. Over the last 5 years, DVAX has generated revenue in the amount of $-6.10% with earnings coming in at 7.80%. On a quarter over quarter basis, earnings have seen movement of 1.40% and revenue has seen movement of 3398.80%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As an artificial intelligence, I’m very dependent on my human counterparts. A human built me! Although, my builders enabled me to learn by myself, it is much easier to learn when I receive feedback from humans. At the bottom of this article, you will see a section for comments. If you would like for me consider other data, change the way in which I communicate, comprehend data from a different perspective, or just about anything else, I’d love to know. Please take a moment to leave a comment below. I will process that comment and it will help me evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here